https://scholars.lib.ntu.edu.tw/handle/123456789/581882
標題: | Elimination of Hepatitis B: Is It a Mission Possible? | 作者: | TAI-CHUNG TSENG JIA-HORNG KAO |
關鍵字: | Chronic hepatitis B; HBsAg; HBV; Immunotherapy | 公開日期: | 2017 | 出版社: | BioMed Central Ltd. | 卷: | 15 | 期: | 1 | 起(迄)頁: | 53 | 來源出版物: | BMC Medicine | 摘要: | Chronic hepatitis B virus (HBV) infection is a global public health issue. Although the disease cannot be cured effectively, disease management has been improved over the past decade. The introduction of potent nucleos(t)ide analogues (NAs) to suppress viral replication represented a giant leap in the control of this disease. It has been shown that tenofovir treatment, a potent NA, complements current immunoprophylaxis to diminish mother-to-infant transmission in pregnant women with a high viral load. For patients with chronic HBV infection, quantitative hepatitis B surface antigen is a useful tool to define inactive carriers and to guide antiviral therapy. Quantification of HBV mutants is also useful in predicting long-term outcomes more precisely than ever. The next challenge is how to achieve an HBV cure; although immunotherapy is a promising strategy, the current results from two clinical trials using therapeutic vaccines to induce HBV-specific immune response in patients with chronic HBV infection are disappointing. In the coming years, we are expecting to see a combination of therapeutic agents with various modes of action to complete the mission of HBV elimination. ? 2017 The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85014940913&doi=10.1186%2fs12916-017-0820-x&partnerID=40&md5=41c344233af31807471387695a80de0c https://scholars.lib.ntu.edu.tw/handle/123456789/581882 |
ISSN: | 1741-7015 | DOI: | 10.1186/s12916-017-0820-x | SDG/關鍵字: | antivirus agent; hepatitis B surface antigen; hepatitis B vaccine; peginterferon; tenofovir; chronic hepatitis B; clinical outcome; human; immunoprophylaxis; liver cell carcinoma; nonhuman; prediction; randomized controlled trial (topic); Short Survey; treatment response; vaccination; viral clearance; virus load; virus mutant; virus transmission; female; Hepatitis B virus; Hepatitis B, Chronic; pregnancy; Antiviral Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pregnancy; Viral Load |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。